Jupiter Asset Management Ltd. Grows Stock Position in Elanco Animal Health Incorporated $ELAN

Jupiter Asset Management Ltd. boosted its holdings in Elanco Animal Health Incorporated (NYSE:ELAN) by 14.2% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,869,942 shares of the company’s stock after buying an additional 233,163 shares during the period. Jupiter Asset Management Ltd. owned 0.38% of Elanco Animal Health worth $26,703,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of ELAN. Allworth Financial LP boosted its position in shares of Elanco Animal Health by 198.9% in the second quarter. Allworth Financial LP now owns 7,035 shares of the company’s stock worth $100,000 after acquiring an additional 4,681 shares during the last quarter. ProShare Advisors LLC grew its stake in shares of Elanco Animal Health by 8.7% during the 2nd quarter. ProShare Advisors LLC now owns 12,439 shares of the company’s stock valued at $178,000 after buying an additional 999 shares during the period. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Elanco Animal Health during the 2nd quarter valued at $3,986,000. RWA Wealth Partners LLC acquired a new stake in shares of Elanco Animal Health during the 2nd quarter worth $538,000. Finally, Paradigm Asset Management Co. LLC purchased a new position in shares of Elanco Animal Health in the 2nd quarter worth $848,000. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Price Performance

Shares of ELAN stock opened at $22.03 on Thursday. The firm has a market cap of $10.95 billion, a P/E ratio of 367.26, a P/E/G ratio of 3.11 and a beta of 1.71. The firm has a fifty day moving average of $20.44 and a two-hundred day moving average of $16.49. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.40 and a quick ratio of 1.23. Elanco Animal Health Incorporated has a 1-year low of $8.02 and a 1-year high of $23.09.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $0.19 EPS for the quarter, topping the consensus estimate of $0.13 by $0.06. The business had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.09 billion. Elanco Animal Health had a net margin of 0.78% and a return on equity of 7.41%. The company’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same quarter last year, the company posted $0.13 earnings per share. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS. Q4 2025 guidance at 0.090-0.120 EPS. As a group, research analysts anticipate that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. Wall Street Zen lowered Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Sunday, November 2nd. Piper Sandler increased their price objective on shares of Elanco Animal Health from $12.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, August 11th. Leerink Partners upgraded shares of Elanco Animal Health from a “market perform” rating to an “outperform” rating and set a $18.00 target price on the stock in a report on Thursday, July 17th. JPMorgan Chase & Co. raised Elanco Animal Health from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $18.00 to $24.00 in a research report on Tuesday, October 7th. Finally, Leerink Partnrs upgraded Elanco Animal Health from a “hold” rating to a “strong-buy” rating in a research note on Thursday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $20.29.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.